Envoy Medical (NASDAQ:COCH) is a U.S.-based medical device company that specializes in developing, manufacturing, and marketing fully implantable hearing systems. Its flagship product, the Esteem® Fully Implantable Hearing System, is designed to address sensorineural hearing loss through a surgical implant that bypasses damaged middle-ear structures. By converting sound waves into mechanical vibrations and directly stimulating the cochlea, the Esteem system aims to provide a more natural listening experience without reliance on external hardware.
Founded in 2002 and headquartered in White Bear Lake, Minnesota, Envoy Medical secured U.S. Food and Drug Administration (FDA) approval for the Esteem system in 2010 and subsequently initiated commercial distribution in 2015. The company’s activities encompass research and development, clinical training for otologic surgeons, and ongoing post-market support. Envoy maintains a network of certified implanting surgeons and audiologists across the United States to ensure appropriate patient candidacy evaluation, surgical implantation, and device programming.
Envoy’s leadership team is led by President and Chief Executive Officer Michael DiBerard, an industry veteran with extensive experience in medical device commercialization and corporate strategy. The company’s board and advisory panels feature experts in otology, audiology, and biomedical engineering who guide clinical research initiatives and product enhancements.
While Envoy Medical currently focuses on the U.S. market, the company continues to explore regulatory pathways in international markets and strategic partnerships to broaden geographic adoption. Ongoing clinical studies aim to refine patient outcomes and extend the benefits of its fully implantable hearing technology to a wider patient population.
